GlassScriptPhysician profile
Jeremy Ray Crisp
NPI 1205035342
$5,145.94
in general payments reported to CMS, 2019-2025
46 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $282 · 2021: $75.55 · 2022: $865 · 2023: $942 · 2024: $1,264 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,374.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $679.71 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $595.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $412.38 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $367.38 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $339.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $319.54 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $313.56 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $243.47 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.34 | 2019-2025 | Jardiance |
| Inari Medical, INC. | $171.42 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sanofi-Aventis U.S. LLC | $136.58 | 2019-2025 | |
| Glaxosmithkline, LLC. | $128.52 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $113.96 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.15 | 2020-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $92.78 | 2022-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Crisp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.